KPV: What the Evidence Actually Shows

Search "KPV peptide" and it's usually pitched as a gentler, gut-focused relative of BPC-157 — marketed for inflammatory bowel symptoms, skin healing, and general anti-inflammatory support, often alongside a claim that it's "backed by research." Some of that research is real, and KPV's mechanism is unusually well characterized at the molecular level compared to a lot of what's sold in the same market. What most product pages don't volunteer is what a direct search of the published literature actually turns up on the human side: as of this review, not one completed human clinical trial, case series, or case report of KPV could be located, anywhere. Not thin — zero. This article traces the animal evidence, the human evidence (and what's often mistaken for it), and the current regulatory record to their actual sources.

What KPV actually is

KPV takes its name from the three amino acids that make it up — lysine, proline, valine — and it isn't a synthetic invention with no natural counterpart. It's the exact C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), residues 11 through 13 of that 13-amino-acid hormone, which is itself cleaved from the larger precursor protein proopiomelanocortin (POMC)¹. Multiple independent papers identify it the same specific way, as "alpha-MSH(11-13)," not as a loosely related "MSH fragment"². A 2004 study of human keratinocyte signaling adds the detail that explains why researchers zeroed in on this exact three-residue piece: KPV is described as one of "the smallest minimal sequences reported to prevent inflammation" within the alpha-MSH sequence — the shortest fragment that still carries the parent hormone's anti-inflammatory activity, without alpha-MSH's own side effect of darkening skin³.

Mechanistically, KPV's most specific, independently replicated detail is its route into cells. A 2008 study found KPV is taken up by PepT1, a di/tripeptide transporter normally expressed at low levels in the small intestine and upregulated in the colon during active inflammatory bowel disease. Once inside cultured human intestinal epithelial cells and human T cells, nanomolar concentrations of KPV inhibited NF-kB and MAP-kinase inflammatory signaling and reduced pro-inflammatory cytokine secretion⁴. That PepT1-uptake detail matters for anyone assuming KPV works the same way everywhere alpha-MSH might: the pathway is tied to a transporter that's most active in gut tissue specifically, not a universal delivery mechanism automatically present in skin or elsewhere in the body.

What the animal evidence actually shows

The published KPV literature is overwhelmingly a colitis and inflammatory bowel disease story, built by a small number of research groups over roughly two decades, and it's genuinely substantial, reasonably consistent work — not an obviously thin or contradictory body of research. Representative findings, read from the studies' own results sections:

• •Foundational colitis study, mice (2008). KPV treatment in DSS-induced colitis produced earlier recovery and significantly stronger regain of body weight, along with reduced inflammatory infiltrates and colonic myeloperoxidase activity. In a second model (CD45RB(hi) transfer colitis), KPV again produced recovery and reduced inflammatory changes. In mice bred with a nonfunctional melanocortin-1 receptor, KPV treatment "rescued all animals in the treatment group from death" during DSS colitis — evidence the effect isn't fully dependent on that one receptor².
• •PepT1 mechanism confirmed in a second colitis model (2008). Oral KPV, added to drinking water, reduced the incidence of both DSS- and TNBS-induced colitis in mice, tracked by reduced pro-inflammatory cytokine expression⁴.
• •Colitis-associated cancer, mice (2016). In a study of PepT1's role in colon cancer arising from chronic inflammation, KPV prevented tumor formation in normal mice that overexpress PepT1 — but had no protective effect at all in mice with PepT1 genetically deleted. That's a direct test of the mechanism, not just the peptide's presence: without the transporter, KPV didn't do anything⁵.
• •Engineered oral delivery, mice (2017) and rats (2021). Two newer drug-delivery papers build on the same base rather than testing anything new about KPV itself: nanoparticles targeting KPV to colonic tissue reduced mucosal damage and downregulated TNF-alpha more effectively than unencapsulated KPV in a mouse ulcerative-colitis model⁶, and a rectal hydrogel formulation reduced weight loss, disease-activity scores, and colonic inflammation markers in a rat TNBS-colitis model⁷.

Two recent reviews synthesizing this literature both frame it the same way — real, accumulating, and still entirely preclinical. A 2023 review of the melanocortin system in inflammatory bowel disease treats the mouse-colitis work, KPV included, as a potential source of "new drugs for treating IBD"⁸. A 2025 review of host-defense peptides for IBD groups KPV alongside several other investigational anti-inflammatory peptides as a promising but still-preclinical drug lead⁹. Neither review reports a completed human trial, for the same reason the next section doesn't either: none currently appears to exist.

What the human evidence actually shows

This is the shortest section in this article, and shorter than the equivalent section in every other evidence review PeptideRank has published on this exact topic. A direct PubMed search for KPV combined with clinical-trial, randomized, or human-patient terms returns results that, read individually, are the same mouse and rat colitis studies covered above — matched only because their methods sections mention cultured human cell lines used to study mechanism, not because any study dosed a living human being. A parallel search of ClinicalTrials.gov for "KPV," "Lysine-Proline-Valine," and "alpha-MSH 11-13" returns zero matching registered trials.

What does exist, and is worth being precise about because it's easy to mistake for "human evidence" if a title is skimmed rather than read in full, falls into two categories — human material, but not a living, dosed human subject:

• •In vitro human cell lines. A 2004 study exposed cultured human keratinocytes to KPV and measured intracellular calcium and cyclic-AMP signaling — a receptor mechanism study, not a treatment outcome³. A 2012 study exposed a cultured human bronchial epithelial cell line to KPV and measured NF-kB signaling and chemokine secretion — again a mechanism study in a dish¹¹. A 2025 study exposed cultured human keratinocytes to airborne particulate matter and found that KPV pretreatment reduced the resulting cell death and inflammatory signaling, including in a 3D lab-grown skin model¹⁰. All three are legitimate published science. None of them is a person.
• •Ex vivo human skin. A 2017 pharmaceutics study measured how well KPV penetrates dermatomed human skin — skin removed during surgery, not a living volunteer's arm — using iontophoresis and microneedles to improve delivery across it. It answers "can KPV be pushed through skin faster with this technique," not "does KPV do anything therapeutic once it's through"¹².

None of that is a clinical trial, and none of it measures a health outcome in a living, dosed human subject. This article isn't implying otherwise by omission: reporting it accurately means being explicit that "tested on human cells" and "tested on human skin" are different claims from "tested in human clinical trials," and for KPV specifically, that third category currently has zero entries.

One more thing worth flagging for anyone weighing that gap against how the peptide is actually sold: a 2026 review of peptide use in recreational and competitive sport lists KPV, alongside several other unapproved research peptides, among the compounds circulating in bodybuilding and gym communities, and states directly that "the clinical evidence supporting peptide use in sport is limited" across that entire category — not a KPV-specific finding, but a direct statement, from a paper surveying exactly this landscape, that the market for these peptides has outrun the trial data behind them¹³.

The current FDA and compounding status

KPV has never had an FDA-approved drug product. A direct, live check against DailyMed, the National Library of Medicine's official archive of FDA-approved drug labeling, returns zero results for "KPV." Its compounding status has moved, and moved recently, the same way several other research peptides have: FDA placed KPV in Category 2 of its interim 503A bulk-substances list — substances presenting significant safety risks that pharmacies should not compound — in 2023, then removed it from Category 2 on April 15, 2026 (effective April 22), alongside eleven other peptides including BPC-157 and TB-500, because the nomination behind that listing was withdrawn. That removal is a procedural change, not an FDA safety finding, and it does not by itself make compounding KPV legal¹⁵.

On July 23, 2026, FDA's own Pharmacy Compounding Advisory Committee (PCAC) formally reviewed "KPV-related bulk drug substances (KPV (free base)/ KPV acetate)" for inclusion on the 503A Bulks List. FDA's own "Uses evaluated" column for KPV, read directly from its meeting page, is "Wound healing and inflammatory conditions"¹⁴ — a broader listed use than BPC-157's ("Ulcerative colitis (UC)") or TB-500's ("Wound healing"), which tracks with KPV's own preclinical literature spanning colitis, oral mucositis, and skin-inflammation models rather than one single condition. The committee voted 8-6, with one abstention, to recommend KPV for the list — the identical tally BPC-157 and TB-500 each received at the same two-day meeting¹⁵. That is a recommendation, not a rule. Formal notice-and-comment rulemaking had not started as of this review, and FDA can accept, modify, reject, or simply sit on a PCAC recommendation. As of this writing, KPV has no approved product, no FDA-set dosing standard, and a compounding status that is recommended but not finalized.

What this means if you're considering a compounded KPV product

Put the two halves of this record side by side and the picture is more lopsided than it is for KPV's better-known peptide-market neighbors. The animal literature is genuinely substantial — a specific, independently replicated transporter mechanism (PepT1), multiple research groups, several different colitis-induction models across mice and rats, and newer drug-delivery engineering built on top of that same base, all pointing the same direction. The human literature, measured the same way this site measures BPC-157's and TB-500's, isn't thin — it's empty. No completed clinical trial. No case series. No case report. No registered ClinicalTrials.gov study under any of KPV's names. What exists instead is a small set of in vitro human cell-line experiments and one ex vivo human skin-penetration study — real published science, but neither category tells you what happens when a person actually takes the peptide, at what dose, for how long, or with what balance of benefit and risk.

That gap matters most for the "gut-healing" framing KPV is usually sold under, since it's exactly the claim with no living-human data behind it, at any dose, in any formulation, from any research group located here. It also means there's no human safety record at all to weigh against a compounded product's own separate unknowns — actual purity, actual peptide content, contamination — the way even BPC-157's three small pilot studies or TB-500's thin-but-real literature at least establish some clinician-observed reference point. Our KPV reconstitution calculator does the vial-to-syringe arithmetic and covers the current compounding-status caution in more detail; it does not, and cannot, supply the missing piece this article documents, because that piece doesn't currently exist in the published record.